{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:14:13Z","timestamp":1785248053188,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of our study is to investigate the effectiveness and safety of the treatment, based on vertigo diaries and pure tone audiograms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The complete medical documentation of 105 definite patients suffering from M\u00e9ni\u00e8re\u2019s disease was analyzed. In the studied group, nine patients were treated with intratympanic gentamycine. Long-term follow-up of the patients was carried out, using vertigo diaries, medical letters, anamnestic data, and pure tone audiograms. Audiometric results and vertigo complaints before and after treatment were contrasted using IBM SPSS V24 software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on our analysis, vertigo attacks appeared significantly less often after gentamycine treatment [<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; Odds ratio 0.003 (95% CI 0.001\u20130.012)], which confirms the efficacy of the therapy. Pure tone stages before and after the application of gentamycine were contrasted using the Mann\u2013Whitney <jats:italic>U<\/jats:italic> test. When comparing the audiometric results of long-term follow-ups by using the logistic regression, a statistically significant difference was observed between the treated and not treated groups [<jats:italic>p<\/jats:italic>\u2009=\u20090.001; Odds ratio 0.141 (95% CI 0.064\u20130.313)], and based on the survivorship curve hearing impairment was more common in the not treated group which also supports our results. Based on the non-parametric test, there was no significant difference (<jats:italic>p<\/jats:italic>\u2009=\u20090.84) between the pure-tone stages of the control group and of those treated with gentamycine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicate that intratympanic gentamycine is effective in controlling vertigo attacks, and there is no higher risk for hearing loss than in case of spontaneous progression of the disorder.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-020-05901-3","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T13:03:42Z","timestamp":1585573422000},"page":"1949-1954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intratympanic gentamycine for M\u00e9ni\u00e8re\u2019s disease: is there a selective vestibulotoxic effect?"],"prefix":"10.1007","volume":"277","author":[{"given":"Andr\u00e1s","family":"Moln\u00e1r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Maihoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"G\u00e1borj\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Tam\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Szirmai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"5901_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00405-018-5260-5","volume":"276","author":"Q Wu","year":"2019","unstructured":"Wu Q, Li X, Sha Y, Sha Y, Dai C (2019) Clinical features and management of Meniere\u2019s disease patients with drop attacks. Eur Arch Otorhinolaryngol 276:665","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"5901_CR2","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.anorl.2017.12.006","volume":"135","author":"J Nevoux","year":"2018","unstructured":"Nevoux J, Barbara M, Dornhoffer J, Gibson W, Kitahara T, Darrouzet V (2018) International consensus (ICON) on treatment of M\u00e9ni\u00e8re\u2019s disease. Eur Ann Otorhinolaryngol Head Neck Dis 135:S29\u2013S32","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"5901_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00005537-200303000-00013","volume":"113","author":"N Perez","year":"2013","unstructured":"Perez N, Mart\u00edn M, Garc\u00eda-Tapia R (2013) Intratympanic gentamicin for intractable Meniere\u2019s disease. Laryngoscope 113:456\u2013464","journal-title":"Laryngoscope"},{"key":"5901_CR4","first-page":"1","volume":"132","author":"HF Schuknecht","year":"1957","unstructured":"Schuknecht HF (1957) Ablation therapy in the management of M\u00e9ni\u00e8re\u2019s disease. Acta Otolaryngol Suppl 132:1\u201342","journal-title":"Acta Otolaryngol Suppl"},{"key":"5901_CR5","first-page":"406","volume":"11","author":"D Bagger-Sjoback","year":"1990","unstructured":"Bagger-Sjoback D, Bergenius J, Lunberg AM (1990) Inner ear effects of topical gentamicin treatment in patients with M\u00e9ni\u00e8re\u2019s disease. Am J Otol 11:406\u2013410","journal-title":"Am J Otol"},{"key":"5901_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10162-007-0093-8","volume":"8","author":"S Lyford-Pike","year":"2007","unstructured":"Lyford-Pike S, Vogelheim C, Chu E, Della Santina CC, Carey JP (2007) Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration. J Assoc Res Otolaryngol 8:497\u2013508","journal-title":"J Assoc Res Otolaryngol"},{"key":"5901_CR7","doi-asserted-by":"publisher","first-page":"E52","DOI":"10.1503\/cmaj.140339","volume":"187","author":"J Leis","year":"2015","unstructured":"Leis J, Rutka J, Gold W (2015) Aminoglycoside-induced ototoxicity. CMAJ 187:E52","journal-title":"CMAJ"},{"key":"5901_CR8","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1002\/lary.21075","volume":"120","author":"K Helling","year":"2010","unstructured":"Helling K, Heinrich UR, Heusgen L, Brieger J, Schmidtmann I, Li H, Mann WJ (2010) Gentamicin alters nitric oxide production in semicircular canals and otolith organs. Laryngoscope 120:2125\u20132128","journal-title":"Laryngoscope"},{"key":"5901_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40136-014-0055-8","volume":"2","author":"MW Miller","year":"2014","unstructured":"Miller MW, Agrawal Y (2014) Intratympanic therapies for Meni\u00e8re\u2019s disease. Curr Otorhinolaryngol Rep 2:137\u2013143","journal-title":"Curr Otorhinolaryngol Rep"},{"key":"5901_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1080\/00016489.2019.1658898","volume":"139","author":"A Moln\u00e1r","year":"2019","unstructured":"Moln\u00e1r A, Maihoub S, Tam\u00e1s L, Szirmai \u00c1 (2019) Intratympanically administered steroid for progressive sensorineural hearing loss in M\u00e9ni\u00e8re\u2019s disease. Acta Otolaryngol 139:982\u2013986","journal-title":"Acta Otolaryngol"},{"key":"5901_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/00005537-200401000-00018","volume":"114","author":"G Lange","year":"2004","unstructured":"Lange G, Maurer J, Mann W (2004) Long-term results after interval therapy with intratympanic gentamicin for M\u00e9ni\u00e8re\u2019s disease. Laryngoscope 114:102\u2013105","journal-title":"Laryngoscope"},{"key":"5901_CR12","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1097\/00005537-199810000-00005","volume":"108","author":"SG Harner","year":"1998","unstructured":"Harner SG, Kasperbauer JL, Facer GW, Beatty CW (1998) Transtympanic gentamicin for Meniere\u2019s syndrome. Laryngoscope 108:1446\u20131449","journal-title":"Laryngoscope"},{"key":"5901_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2273.1990.tb00796.x","volume":"15","author":"K Laitakari","year":"1990","unstructured":"Laitakari K (1990) Intratympanic gentamycin in sever M\u00e9ni\u00e8re\u2019s disease. Clin Otolaryngol Allied Sci 15:545\u2013548","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"5901_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/VES-150549","volume":"25","author":"JA Lopez-Escamez","year":"2015","unstructured":"Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandal\u00e0f M, Newman-Tokerg DE, Strupph M, Suzukii M, Trabalzinif F, Bisdorff A (2015) Diagnostic criteria for Meni\u00e8re\u2019s disease. J Vest Res 25:1\u20137","journal-title":"J Vest Res"},{"key":"5901_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1080\/00016480701762458","volume":"128","author":"RJ Postema","year":"2008","unstructured":"Postema RJ, Kingma CM, Wit HP, Albers FWJ, Van Der Laan BFAM (2008) Intratympanic gentamicin therapy for control of vertigo in unilateral Meni\u00e8re\u2019s disease: a 7 prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol 128:876\u2013880","journal-title":"Acta Otolaryngol"},{"key":"5901_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF00455886","volume":"221","author":"C Beck","year":"1978","unstructured":"Beck C, Schmidt CL (1978) 10 years of experience with intratympanically applied streptomycin (gentamycin) in the therapy of Morbus Meniere. Arch Otorhinolaryngol 221:149\u2013152","journal-title":"Arch Otorhinolaryngol"},{"key":"5901_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1177\/0194599813520398","volume":"150","author":"AP Casani","year":"2014","unstructured":"Casani AP, Cerchiai N, Navari E, Dallan I, Piaggi P, Sellari-Franceschini S (2014) Intratympanic gentamicin for Meniere\u2019s disease: short-and long-term follow-up of two regimens of treatment. Otolaryngol Head Neck Surg 150:847\u2013852","journal-title":"Otolaryngol Head Neck Surg"},{"key":"5901_CR18","first-page":"383","volume":"9","author":"C M\u00f6ller","year":"1988","unstructured":"M\u00f6ller C, Odkvist LM, Thell J, Larsby B, Hyd\u00e9n D (1988) Vestibular and audiologic functions in gentamicin-treated Meni\u00e8re\u2019s disease. Am J Otol 9:383\u2013391","journal-title":"Am J Otol"},{"key":"5901_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2273.1990.tb00796.x","volume":"15","author":"K Laitakari","year":"1990","unstructured":"Laitakari K (1990) Intratympanic gentamycin in severe M\u00e9ni\u00e8re\u2019s disease. Clin Otolaryngol Allied Sci 15:545\u2013548","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"5901_CR20","first-page":"361","volume":"26","author":"M Corsten","year":"1997","unstructured":"Corsten M, Marsan J, Schramm D, Robichaud J (1997) Treatment of intractable Meni\u00e8re\u2019s disease with intratympanic gentamicin: review of the University of Ottawa experience. J Otolaryngol 26:361\u2013364","journal-title":"J Otolaryngol"},{"key":"5901_CR21","first-page":"209","volume":"20","author":"JT Atlas","year":"1999","unstructured":"Atlas JT, Parnes LS (1999) Intratympanic gentamicin titration therapy for intractable Meniere\u2019s disease. Am J Otol 20:209\u2013219","journal-title":"Am J Otol"},{"key":"5901_CR22","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/0194599811429432","volume":"146","author":"AP Casani","year":"2012","unstructured":"Casani AP, Piaggi P, Cerchiai N, Seccia V, Franceschini SS, Dallan I (2012) Intratympanic treatment of intractable unilateral Meniere disease: gentamicin or dexamethasone? A randomized controlled trial. Otolaryngol Head Neck Surg 146:430\u2013437","journal-title":"Otolaryngol Head Neck Surg"},{"key":"5901_CR23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/MAO.0b013e318259b3b1","volume":"33","author":"L Huon","year":"2012","unstructured":"Huon L, Fang T, Wang P (2012) Outcomes of intratympanic gentamicin injection to treat M\u00e9ni\u00e8re\u2019s disease. Otol Neurotol 33:706\u2013714","journal-title":"Otol Neurotol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-020-05901-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00405-020-05901-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-020-05901-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T23:24:29Z","timestamp":1617060269000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00405-020-05901-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["5901"],"URL":"https:\/\/doi.org\/10.1007\/s00405-020-05901-3","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All of the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}